Liquid Biopsy for Mutation Burden Predicts PFS in NSCLC Immunotherapy – OncLive
OncLive |
Liquid Biopsy for Mutation Burden Predicts PFS in NSCLC Immunotherapy
OncLive A liquid biopsy that measures tumor mutational burden showed promise as an aid for predicting benefit in patients with non–small cell lung cancer (NSCLC) treated with a checkpoint inhibitor, a retrospective analysis of a randomized study showed. |
